

Table E6. Correlation of the changes from baseline to week 32 between visual acuity outcomes and retinal ganglion cell thickness (RNFL), visual pathway electrophysiological function (VEP P100 latency and amplitude) and patient-reported visual function (NEI-VFQ-25 and NOS-10) in RENEW participants by treatment group. This analysis was performed in the

PP population.	Placebo			Opicinumab		
	HCVA	1.25% LCLA	2.5% LCLA	HCVA	1.25% LCLA	2.5% LCLA
Mean SD-OCT RNFL thickness (microns)	0.03 (n=34)	0.39 (n=34)	0.45 (n=34)	0.06 (n=31)	0.22 (n=30)	0.40 (n=30)
Mean FF-VEP amplitude (uVolts)	0.03 (n=35)	-0.09 (n=35)	-0.11 (n=35)	-0.23 (n=30)	-0.16 (n=29)	-0.29 (n=29)
Mean FF-VEP latency (msec)	-0.26 (n=35)	-0.57 (n=35)	-0.51 (n=35)	-0.13 (n=30)	0.01 (n=29)	-0.12 (n=29)
NEI-VFQ-25 composite score	-0.03 (n=35)	-0.00 (n=35)	0.04 (n=35)	-0.08 (n=30)	-0.01 (n=29)	-0.14 (n=29)
NOS-10 composite score	-0.05 (n=34)	-0.21 (n=34)	-0.13 (n=34)	0.01 (n=28)	0.36 (n=28)	0.28 (n=28)
HCVA	-	0.20 (n=36)	0.42 (n=36)	-	0.16 (n=30)	0.43 (n=30)
1.25% LCLA	0.20 (n=36)	-	0.77 (n=36)	0.16 (n=30)	-	0.76 (n=30)
2.5% LCLA	0.42 (n=36)	0.77 (n=36)	-	0.43 (n=30)	0.76 (n=30)	-

FF-VEP, full-field visual evoked potential; HCVA, high-contrast visual acuity; NEI-VFQ-25, 25-item National Eye Institute Visual Functioning Questionnaire; NOS-10, 10-item Neuro-Ophthalmic Supplement; RNFL, retinal nerve fiber layer; SD-OCT, spectral-domain optical coherence tomography.

Mean change in RNFL thickness, FF-VEP, HCVA and LCLA at week 32 is the change for the affected eye at week 32 from the baseline of the unaffected fellow eye.